Navigation Links
Gene Signal Enters Phase III Clinical Tests for the Prevention of Corneal Graft Rejection

- Gene Signal International, a Biotech Company Registered in

Switzerland, Will Move its Headquarter to the EPFL, in Lausanne,

- Gene Signal is Addressing Various Issues Related to Neovascularisation,

- Gene Signal is Working on a Portfolio of Ophthalmologic Indications,

With One Now in Phase III Trials

- Gene Signal Will Present its Interim Results at the Annual Meeting of

the American Academy of Ophtalmologist in Atlanta, USA, the

Largest Scientific Convention in this Field

Gene Signal, a biotech company registered in Switzerland, is currently starting the Phase III study of GS-101, its most advanced therapeutic ophthalmic solution, for the prevention of corneal graft rejection.

Every year, over 40'000 corneal grafts are performed worldwide to cure or prevent blindness, thus making this procedure the most frequently performed transplant surgery. However, the 5 year failure rate for corneal grafts is currently around 35%. As many other graft procedures, donor grafts are always in limited supply. A failure is even more "wasteful" in this context of long waiting lines (6 months - 2 years).

One of the main reasons for graft failure is the immune response of the body. Normally, the cornea is avascular (i.e. deprived of blood vessels), protecting the donor cornea from being rejected. However, under certain circumstances, new blood vessel creation (neovascularization) occurs, inducing an immune response to the donor graft that can lead to immunological corneal graft rejection.

Currently, there is no therapy available. Gene Signal is working on new ways to prevent this syndrome. With its antisense oligonucleotide approach, it aims to block the pathways leading to the formation of blood vessels in the cornea. This approach uses short DNA fragments that specifically target and block the production of a protein that is required for the formation and growth of new blood vessels.

GS 101 eye drops have successfully completed the phase II study. The results show a significant regression of corneal neovascularization, whereas the placebo group all showed an increase in new vessels.

"These interim results (of a phase II study) suggest GS101 eye drops to be an effective and safe approach to specifically inhibit and regress active corneal neovascularization, a major risk factor for corneal graft rejection", indicated Professor Claus Cursiefen, of the Department of Ophthalmology, Friedrich Alexander University, in Germany.

"Compared to the placebo group with 100% ongoing progression of corneal neovascularisation over the 3-month period, the optimal treatment group achieved 86% regression and progression in only 14%", he added.

Prof. Cursiefen will take advantage of the world's largest gathering for ophthalmologists, the Annual Meeting of the American Association of Ophtalmologist in Atlanta, USA, on November 8 - 11, 2008, to present these promising results.

In parallel, Gene Signal is developing a diverse pipeline of novel antisense oligonucleotides, proteins and monoclonal antibodies to treat a range of angiogenesis based diseases. It is evaluating three new drugs in ophthalmology as well as in dermatology and is in the discovery phase with four more molecules addressing indications in the field of vascular disease and oncology.

About Gene Signal

Gene Signal ( is a biotechnology company focused on discovering genes involved in the regulation of angiogenesis. Founded in 2000, the company has assembled an outstanding leadership team that includes scientific, medical, regulatory, and business professionals with successful track records in developing and bringing to market state of the art drugs. Gene Signal continues to develop its angiogenesis modulating technology and has built a significant intellectual property portfolio, as well as a robust clinical and preclinical pipeline. The company's Headquarter will soon move to Lausanne, Switzerland, with its research program in France, and product development in Canada. Gene Signal is currently looking for licensing partners to either commercialize or co-develop our therapeutic portfolio.


Gene Signal

Eric Viaud


Gene Signal International SA

Chemin Champ Rond, 53

1010 Lausanne


Tel: +41-21-804-61-64

Fax: +41-21-804-61-65

Mobile: +41-79-774-20-72



Rochat & Partners

Gael Le Corre-Laliberte


SOURCE Gene Signal International SA
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Revealing the regulating mechanism behind signal transduction in the brain
2. Signalife Announces Reverse Stock Split, Preferred Stock Dividend and $5 Million Investment
3. Signalife Announces Anticipated Date of Transition to OTCBB
4. Signalife to Issue Breaking News Regarding Vianale & Vianale Tomorrow
5. Signalife Announces Intent to Withdraw From AMEX and Trade on the OTCBB
6. AFL To Return to Oklahoma Due to Overwhelming Demand for Signalife Heart Screening
7. Signalife Board Approves Merger
8. Signalife Announces AFL Joins NIH Education Program
9. Signalife Appoints Lee Ehrlichman President and Chief Operating Officer
10. Signalife Appoints Lee Ehrlichman as Company Director and Operations Director; Additional Notice Received From Amex Regarding Sharholders Equity Deficiency
11. Signalife Awarded New U.S. Patent, System For, And Method Of, Monitoring Heartbeats Of A Patient
Post Your Comments:
(Date:11/25/2015)... /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS; TSX: AEZ) ... remain fundamentally strong and highlights the following developments: ... DSMB recommendation to continue the ZoptEC Phase 3 ... final interim efficacy and safety data , ... with heavily pretreated castration- and Taxane-resistant prostate cancer ...
(Date:11/24/2015)... KUALA LUMPUR, Malaysia , Nov. 24, 2015 ... the global contract research organisation (CRO) market. The ... to result in lower margins but higher volume ... With increased capacity and scale, however, margins in ... Contract Research Organisation (CRO) Market ( ...
(Date:11/24/2015)... ... November 24, 2015 , ... Copper is ... it is bound to proteins, copper is also toxic to cells. With a ... Polytechnic Institute (WPI) will conduct a systematic study of copper in the bacteria ...
(Date:11/24/2015)... ... , ... This fall, global software solutions leader SAP and AdVenture Capital brought ... pitch their BIG ideas to improve health and wellness in their schools. , Now, ... the title of SAP's Teen Innovator, an all-expenses paid trip to Super Bowl 50, ...
Breaking Biology Technology:
(Date:11/10/2015)... 10, 2015  In this report, the ... of product, type, application, disease indication, and ... report are consumables, services, software. The type ... biomarkers, efficacy biomarkers, and validation biomarkers. The ... diagnostics development, drug discovery and development, personalized ...
(Date:11/2/2015)... 2, 2015  SRI International has been awarded a ... development services to the National Cancer Institute (NCI) PREVENT ... scientific expertise, modern testing and support facilities, and analytical ... and toxicology studies to evaluate potential cancer prevention drugs. ... PREVENT Cancer Drug Development Program is an NCI-supported pipeline ...
(Date:10/29/2015)... Oct. 29, 2015  Connected health pioneer, Joseph ... explosion of technology-enabled health and wellness, and the business ... The Internet of Healthy Things . ... smartphones even existed, Dr. Kvedar, vice president, Connected Health, ... care delivery, moving care from the hospital or doctor,s ...
Breaking Biology News(10 mins):